145 related articles for article (PubMed ID: 34997316)
1. Cancer worry among BRCA1/2 pathogenic variant carriers choosing surgery to prevent tubal/ovarian cancer: course over time and associated factors.
van Bommel MHD; Steenbeek MP; IntHout J; Hermens RPMG; Hoogerbrugge N; Harmsen MG; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JM; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Prins JB; Custers JAE; de Hullu JA
Support Care Cancer; 2022 Apr; 30(4):3409-3418. PubMed ID: 34997316
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a patient decision aid for BRCA1/2 pathogenic variant carriers choosing an ovarian cancer prevention strategy.
Steenbeek MP; van Bommel MHD; Harmsen MG; Hoogerbrugge N; van Doorn HC; Keurentjes JHM; van Beurden M; Zweemer RP; Gaarenstroom KN; Penders CGJ; Brood-van Zanten MMA; Vos MC; Piek JM; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; IntHout J; de Hullu JA; Hermens RPMG
Gynecol Oncol; 2021 Nov; 163(2):371-377. PubMed ID: 34456057
[TBL] [Abstract][Full Text] [Related]
3. TUBectomy with delayed oophorectomy as an alternative to risk-reducing salpingo-oophorectomy in high-risk women to assess the safety of prevention: the TUBA-WISP II study protocol.
Steenbeek MP; van Bommel MHD; intHout J; Peterson CB; Simons M; Roes KCB; Kets M; Norquist BM; Swisher EM; Hermens RPMG; ; Lu KH; de Hullu JA
Int J Gynecol Cancer; 2023 Jun; 33(6):982-987. PubMed ID: 37045546
[TBL] [Abstract][Full Text] [Related]
4. Association of Salpingectomy With Delayed Oophorectomy Versus Salpingo-oophorectomy With Quality of Life in BRCA1/2 Pathogenic Variant Carriers: A Nonrandomized Controlled Trial.
Steenbeek MP; Harmsen MG; Hoogerbrugge N; de Jong MA; Maas AHEM; Prins JB; Bulten J; Teerenstra S; van Bommel MHD; van Doorn HC; Mourits MJE; van Beurden M; Zweemer RP; Gaarenstroom KN; Slangen BFM; Brood-van Zanten MMA; Vos MC; Piek JMJ; van Lonkhuijzen LRCW; Apperloo MJA; Coppus SFPJ; Massuger LFAG; IntHout J; Hermens RPMG; de Hullu JA
JAMA Oncol; 2021 Aug; 7(8):1203-1212. PubMed ID: 34081085
[TBL] [Abstract][Full Text] [Related]
5. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.
Harmsen MG; Arts-de Jong M; Hoogerbrugge N; Maas AH; Prins JB; Bulten J; Teerenstra S; Adang EM; Piek JM; van Doorn HC; van Beurden M; Mourits MJ; Zweemer RP; Gaarenstroom KN; Slangen BF; Vos MC; van Lonkhuijzen LR; Massuger LF; Hermens RP; de Hullu JA
BMC Cancer; 2015 Aug; 15():593. PubMed ID: 26286255
[TBL] [Abstract][Full Text] [Related]
6. Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
Nebgen DR; Hurteau J; Holman LL; Bradford A; Munsell MF; Soletsky BR; Sun CC; Chisholm GB; Lu KH
Gynecol Oncol; 2018 Jul; 150(1):79-84. PubMed ID: 29735278
[TBL] [Abstract][Full Text] [Related]
7. Risk-Reducing Strategies for Ovarian Cancer in
Tschernichovsky R; Goodman A
Oncologist; 2017 Apr; 22(4):450-459. PubMed ID: 28314837
[TBL] [Abstract][Full Text] [Related]
8. Perceptions of risk and reward in BRCA1 and BRCA2 mutation carriers choosing salpingectomy for ovarian cancer prevention.
Ghezelayagh TS; Stewart LE; Norquist BM; Bowen DJ; Yu V; Agnew KJ; Pennington KP; Swisher EM
Fam Cancer; 2020 Apr; 19(2):143-151. PubMed ID: 32096072
[TBL] [Abstract][Full Text] [Related]
9. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
[TBL] [Abstract][Full Text] [Related]
10. Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations.
Smith MJ; Gerber D; Olsen A; Khouri OR; Wang Y; Liu M; Smith J; Pothuri B
Am J Obstet Gynecol; 2021 Nov; 225(5):508.e1-508.e10. PubMed ID: 34171390
[TBL] [Abstract][Full Text] [Related]
11. Preventing Ovarian Cancer through early Excision of Tubes and late Ovarian Removal (PROTECTOR): protocol for a prospective non-randomised multi-center trial.
Gaba F; Robbani S; Singh N; McCluggage WG; Wilkinson N; Ganesan R; Bryson G; Rowlands G; Tyson C; Arora R; Saridogan E; Hanson H; Burnell M; Legood R; Evans DG; Menon U; Manchanda R;
Int J Gynecol Cancer; 2021 Feb; 31(2):286-291. PubMed ID: 32907814
[TBL] [Abstract][Full Text] [Related]
12. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
13. Salpingectomy With Delayed Oophorectomy in BRCA1/2 Mutation Carriers: Estimating Ovarian Cancer Risk.
Harmsen MG; IntHout J; Arts-de Jong M; Hoogerbrugge N; Massuger LFAG; Hermens RPMG; de Hullu JA
Obstet Gynecol; 2016 Jun; 127(6):1054-1063. PubMed ID: 27159752
[TBL] [Abstract][Full Text] [Related]
14. Uptake of risk-reducing salpingo-oophorectomy among female BRCA mutation carriers: experience at the National Cancer Center of Korea.
Kim SI; Lim MC; Lee DO; Kong SY; Seo SS; Kang S; Lee ES; Park SY
J Cancer Res Clin Oncol; 2016 Jan; 142(1):333-40. PubMed ID: 26438354
[TBL] [Abstract][Full Text] [Related]
15. Contraceptives and cancer risks in BRCA1/2 pathogenic variant carriers: a systematic review and meta-analysis.
van Bommel MHD; IntHout J; Veldmate G; Kets CM; de Hullu JA; van Altena AM; Harmsen MG
Hum Reprod Update; 2023 Mar; 29(2):197-217. PubMed ID: 36383189
[TBL] [Abstract][Full Text] [Related]
16. Study on the psychosocial aspects of risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 mutation carriers in Japan: a preliminary report.
Shigehiro M; Kita M; Takeuchi S; Ashihara Y; Arai M; Okamura H
Jpn J Clin Oncol; 2016 Mar; 46(3):254-9. PubMed ID: 26685323
[TBL] [Abstract][Full Text] [Related]
17. Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution.
Kobayashi Y; Hirasawa A; Chiyoda T; Ueki A; Masuda K; Misu K; Kawaida M; Hayashi S; Kataoka F; Banno K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2021 Feb; 51(2):213-217. PubMed ID: 33037428
[TBL] [Abstract][Full Text] [Related]
18. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
[TBL] [Abstract][Full Text] [Related]
19. Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study.
Grandi G; Sammarini M; Cortesi L; Toss A; Botticelli L; Varliero F; Sighinolfi G; Barbieri E; Facchinetti F
Menopause; 2021 Feb; 28(3):263-270. PubMed ID: 33534430
[TBL] [Abstract][Full Text] [Related]
20. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]